⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13654135 | 0.77 | — | — | |
| SCHEMBL12000471 | 0.77 | HPGD (0.32) | — | |
| SCHEMBL13413937 | 0.77 | TSHR (0.33) | — | |
| SCHEMBL12000486 | 0.77 | HPGD (0.35) | — | |
| SCHEMBL4546371 | 0.74 | GABRA1 (0.37) | — | |
| SCHEMBL12086848 | 0.73 | KDM4E (0.31) | — | |
| SCHEMBL12086918 | 0.73 | — | — | |
| SCHEMBL21787944 | 0.73 | TYR (0.42) | — | |
| SCHEMBL20425075 | 0.72 | EPHX1 (0.37) | — | |
| SCHEMBL23890458 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119346174-A | Hollow porous hydrogenation catalyst, preparation method and application thereof, magnetic hollow porous hydrogenation catalyst and application thereof | 中国制浆造纸研究院有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11873290-B2 | — | — | 2024-01-16 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-4320031-A | Catalytic oxidative dehydrogenation of alkenes or alkadienes to furan compounds | GAF CORPORATION (US) | 1982-03-16 | — | — | US | disclosed |
| US-4309355-A | PROMOTED SILVER-MOLYBDENUM OXIDE CATALYST | GAF CORPORATION (US) | 1982-01-05 | — | — | US | disclosed |
| US-4309356-A | SILVER-MOLYBDENUM OXIDE CATALYST | GAF CORPORATION (US) | 1982-01-05 | — | — | US | disclosed |
| US-4293444-A | SILVER, MOLYBDENUM | GAF CORPORATION (US) | 1981-10-06 | — | — | US | disclosed |
| US-4280959-A | SILVER, PHOSPHORUS, OXYGEN CATALYST | GAF CORPORATION (US) | 1981-07-28 | — | — | US | disclosed |
| EP-0023382-A1 | Olefin oxidation process | THE STANDARD OIL COMPANY (US) | 1981-02-04 | — | — | EP | disclosed |
| EP-0013467-A1 | Process for the manufacture of furan compounds | THE STANDARD OIL COMPANY (US) | 1980-07-23 | — | — | EP | disclosed |
| US-4080312-A | CONTAINING PHOSPHORUS, VANADIUM, OXYGEN, AND MOLYBDENUM | PHILLIPS PETROLEUM COMPANY (US) | 1978-03-21 | — | — | US | disclosed |
| US-4039476-A | PHOSPHORUS, MOLYBDENUM, COBALT, OXYGEN | PHILLIPS PETROLEUM COMPANY (US) | 1977-08-02 | — | — | US | disclosed |
| US-4026820-A | PHOSPHOROUS, IRON, AND OXYGEN | PHILLIPS PETROLEUM COMPANY (US) | 1977-05-31 | — | — | US | disclosed |